http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-034692-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4402
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4402
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D235-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-48
filingDate 2000-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5237c74979d0b78ff48dbb44382db704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_647e7464509dc6d5bb4f76d5dff80b61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73e067141134fb2f0f9718cc9de86722
publicationDate 2004-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AR-034692-A1
titleOfInvention INHIBITORS OF THE INTEGRIN ALFAVBETA3, A PROCEDURE FOR THEIR PREPARATION, THE MEDICATIONS BASED ON THESE COMPOUNDS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THE USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT TO COMBAT DISEASE BASED ON THE EXISTING BASIS
abstract Inhibitors of integrin alfavbeta3 of formula (1) are described: XYZ-R1-CH2-R2 (R4) -CH2-CO-R5, wherein: X means H2N-C (= NH) -, H2N-C (= NH ) -NH, AC (= NH) -NH-, Het1- or Het1-NH-, where the primary amino groups may also be provided with conventional amino protecting groups; Y means - (CH2) n, or a compound of formula (2) where 1, 2, 3 or 4 methylene group may be replaced by N, O and / or S; Z is absent or means -O-, -NH-, -NA-, -CH (OH) -, -CH (OA) -, -CHA-, -CA2- or -S-; R1 means phenylene unsubstituted or substituted 1, 2 or 3 times with F, Cl, Br, A, OA, OCF3 or CN; R2 means N, CH or CA; R3 means H, F, Cl, Br, A, OA or OCF3; R4 means phenyl, naphthyl or Het2 not substituted or substituted once or several times with A, aryl or CF3; R5 means OH, OA, NH2, NHA or NA2; Het1 means a heterocycle of 1 or 2 nuclei with 1 to 4 N atoms, which may be unsubstituted or substituted 1-2 times with NH2; Het2 means an aromatic heterocycle of 1 or 2 nuclei with 1 to 3 atoms of N, O and / or S, which may be unsubstituted or substituted 1 or 2 times with F, Cl, Br, A, OA, SA, OCF3, -CO-A, CN, COOA, CONH2, CONHA, CONA2 or NO2; Aryl means phenyl unsubstituted or substituted 1, 2 or 3 times with Hal, A or OA; A means C1-12 alkyl; n means from 1 to 12; m and or independently of each other mean from 1 to 12; as well as its physiologically harmless salts and solvates. These compounds especially inhibit the interactions of alphav receptors with ligands, being especially effective as ligands of integrin alfavbeta3. A process for preparing the compounds of formula (1), the medicines based on these compounds, the pharmaceutical compositions containing them and the use thereof for the preparation of a medicament for combating diseases based on the disease is also described. expression and pathological function of integrin alfavbeta3 receptors, in particular, to combat thrombosis, myocardial infarction, coronary heart disease, arteriosclerosis, tumors, osteoporosis, fibrosis, inflammations, infections, lapsoriasis, as well as to influence wound healing processes.
priorityDate 1999-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456357891
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396411
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396401
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457444288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393625

Total number of triples: 71.